Editorial |
Featured
-
-
News |
FDA under pressure to relax drug rules
Industry says antibiotic pipeline is being blocked by overly stringent clinical-trial requirements for new treatments.
- Heidi Ledford
-
World View |
Gene therapies need new development models
As with other medicines, the approval of gene therapies should hinge on a risk–benefit analysis for the patient, argues Fulvio Mavilio.
- Fulvio Mavilio
-
News |
Outcry over jailed Russian chemist
Narcotics expert Olga Zelenina falsely accused of aiding drug trafficking, say supporters.
- Quirin Schiermeier
-
News |
FDA’s claims over stem cells upheld
Drug watchdog wins right to regulate controversial therapies.
- David Cyranoski
-
News |
TB drugs chalk up rare win
Combination therapy is just one emerging weapon in the fight against tuberculosis.
- Amy Maxmen
-
News |
Europe nears first approval for gene therapy
Treatment for rare fat-processing disease gains approval from medicines regulator.
- Daniel Cressey
-
News |
Law spurs regulators to heed patients’ priorities
US FDA to consider risks and benefits more explicitly in drug approvals.
- Amy Maxmen
-
News |
Weight-loss drug wins US approval
Obesity treatment shows promise for patients with diabetes despite concerns that it could cause heart complications.
- Brendan Borrell
-
News |
Failings exposed at India’s drug regulator
Inadequate testing and insufficient staffing plague the granting of pharmaceutical licences.
- Gayathri Vaidyanathan
-
Outlook |
Drugs: An injection of hope
For decades, drugs have barely managed to slow the progression of multiple sclerosis. Therapies are now emerging that may even help to reverse the disease — but are they worth the risk?
- Duncan Graham-Rowe
-
News |
International groups move to criminalize fake drugs
Regulations aim to shift medicine counterfeiting from patent infringement to crime.
- Katherine Rowland
-
News |
Childhood drug studies show room for improvement
Report finds recent laws have enhanced US child medicine, but some drugs are still used without rigorous testing.
- Erika Check Hayden
-
News |
FDA unveils biosimilars guidance
Move could open the door to cheaper generic versions of biological drugs.
- Heidi Ledford
-
Editorial |
The morning after
President Barack Obama's stance on an emergency contraceptive betrays his promised principles of scientific integrity and sets a troubling precedent for political interference in 'inconvenient' science.
-
News |
Antibody offers hope for multiple sclerosis treatment
Promising phase III trial paves the way for alemtuzumab approval.
- Duncan Graham-Rowe
-
News |
Malaria vaccine one step closer to approval
Trial results are promising, but marred by poor efficacy against severe forms of the disease.
- Daniel Cressey
-
News |
Charities seek cut of drug royalties
Non-profits that support medical research are angling for a share of the proceeds and intellectual-property rights.
- Heidi Ledford
-
News Explainer |
Death-row drug dilemma
Lack of anaesthetic used in lethal injection exposes ethics gaps in the supply chain.
- Emma Marris
-
News |
'Biosimilar' drugs poised to penetrate market
Draft regulations will pave the way for copycat antibodies and other large molecules.
- Heidi Ledford
-
News |
Mephedrone on borrowed time
'Legal high' set to become illegal despite resignation of crucial drugs adviser.
- Daniel Cressey
